Figure 6
From: MiR-99a may serve as a potential oncogene in pediatric myeloid leukemia
MiR-99a represses expression of CTDSPL and TRIB2 proteins in most clinical samples from AML patients. Western blot showed that the expression level of CTDSPL protein in patients with AML-M3 (A) and AML-M2 (B) and the expression level of TRIB2 protein in patients with AML-M3 (C, D) were relatively high in children in control group (N) and most of the patients in hematological CR; however, the level decreased in most of the patients before treatment (P).